Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that the Company will be attending and presenting at a series of investor events from the 4thSeptember to 10th October 2019.
Cathal Friel, Open Orphan’s Chief Executive Officer, will be in attendance for all of the events and will be presenting to update existing and potential investors on the Company’s business plans for 2019-2020.
No new material information will be disclosed at any event.
A full schedule of the upcoming events is as follows:
|
Event |
Date/Time |
Location |
|
Shares Magazine Investor Evening |
September 4th 2019 18:00 – 21:30 |
London – Novotel Tower Bridge, EC3N 2NR |
|
ShareSoc Growth Company Seminar |
September 11th 2019 17:30 |
London – 65 Gresham Street, London, EC2V 7NQ |
|
London South East Biotech Investor Evening |
September 11th 2019 18:30 |
London – Brewers Hall, Aldermanbury Square, London EC2V 7HR |
|
Shares Magazine Investor Evening |
September 12th 2019 17:20 – 21:30 |
Edinburgh – Radisson Blu Hotel, EH1 1TH |
|
Total Market Solutions |
September 18th 2019 12:30-15:00 |
London, Moorgate |
|
Proactive Investors One2One Forum |
September 18th 2019 18:00 – 20:00 |
London – Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB in the Charles Suite (1st Floor) |
|
Shares Magazine Investor Evening |
October 10th 2019 18:00 |
Manchester – Macdonald Manchester Hotel, M1 2PG |
Enquiries:
Open Orphan Plc Tel: +353 1 5499 341
Cathal Friel, Chief Executive Officer
Arden Partners (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer
Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1 679 6363
Anthony Farrell (Corporate Finance)
Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Billy Clegg / Daniel Sherwen
Notes to Editors:
Open Orphan plc is a European-focussed, rare and orphan drug consulting services platform. The Company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to partner with Patient Advocacy Groups. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.